Abstract
Screening by a double-disk synergy test identified a Pseudomonas aeruginosa isolate that produced a clavulanic acid-inhibited expanded-spectrum beta-lactamase (ESBL). Cloning and sequencing identified a novel ESBL, BEL-1, weakly related to other Ambler class A ESBLs. beta-Lactamase BEL-1 hydrolyzed significantly most expanded-spectrum cephalosporins and aztreonam, and its activity was inhibited by clavulanic acid, tazobactam, cefoxitin, moxalactam, and imipenem. This chromosome-encoded ESBL gene was embedded in a class 1 integron containing three other gene cassettes. In addition, this integron was bracketed by Tn1404 transposon sequences at its right end and by P. aeruginosa-specific sequences at its left end.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Amino Acid Sequence
-
Anti-Bacterial Agents / pharmacology*
-
Clavulanic Acid / pharmacology*
-
Cloning, Molecular
-
DNA, Bacterial / genetics
-
Enzyme Inhibitors / pharmacology*
-
Genes, Bacterial / genetics*
-
Integrons / genetics*
-
Isoelectric Focusing
-
Kinetics
-
Microbial Sensitivity Tests
-
Molecular Sequence Data
-
Plasmids / genetics
-
Pseudomonas aeruginosa / drug effects*
-
Pseudomonas aeruginosa / genetics*
-
Reverse Transcriptase Polymerase Chain Reaction
-
Spectrophotometry, Ultraviolet
-
beta-Lactamase Inhibitors
-
beta-Lactamases / genetics*
-
beta-Lactamases / metabolism
Substances
-
Anti-Bacterial Agents
-
DNA, Bacterial
-
Enzyme Inhibitors
-
beta-Lactamase Inhibitors
-
Clavulanic Acid
-
beta-Lactamases
-
beta-lactamase BEL-1, Pseudomonas aeruginosa